DOPR

coronary artery disease, arrhythmias, hypertension, heart failure

DOx compounds produce sustained cardiovascular stimulation including tachycardia and vasoconstriction. DOPR's 20–30 hour duration means cardiovascular load persists for an entire day-night cycle. Individuals with pre-existing cardiovascular disease, arrhythmias, or hypertension face elevated risk of adverse cardiac events.

epilepsy, seizure disorders

Seizures are documented in DOx-class toxicity presentations. Individuals with epilepsy or other conditions that lower seizure threshold are at elevated risk. No DOPR-specific seizure data exist.

schizophrenia, schizoaffective disorder, psychotic features

DOPR is a potent 5-HT2A full agonist. Serotonergic psychedelics are contraindicated in schizophrenia, schizoaffective disorder, and other psychotic spectrum conditions due to risk of precipitating acute psychotic episodes. Prolonged psychotic states have been reported with DOx compound use at high doses. DOPR's 20–30 hour duration extends the window of psychotic vulnerability.

bipolar I disorder, bipolar II disorder

Serotonergic psychedelics carry risk of triggering manic episodes in individuals with bipolar disorder. DOPR's exceptionally long duration (20–30 hours) extends the period of mood destabilization and sleep deprivation, both of which are known mania triggers.

pregnancy, breastfeeding

No reproductive toxicity data exist for DOPR. Serotonergic psychedelics are contraindicated in pregnancy as a class due to 5-HT2A-mediated uterotonic effects and unknown teratogenic potential. The 20–30 hour duration adds sustained physiological stress.

MAOI medication use, moclobemide, phenelzine, tranylcypromine, selegiline, isocarboxazid

Monoamine oxidase inhibitors block the primary metabolic pathway for DOx compounds (N-deamination), potentially dramatically increasing both intensity and duration of effects. The combination carries risk of serotonin syndrome — a potentially life-threatening toxidrome characterized by hyperthermia, neuromuscular hyperactivity, and autonomic instability.

lithium carbonate, lithium citrate

Lithium is contraindicated with serotonergic psychedelics as a class. The combination lowers seizure threshold and elevates serotonin syndrome risk. Multiple anecdotal reports across the psychedelic class document severe adverse reactions with lithium co-administration.